Healthcare · Medical Devices · United States
As of 2026-04-17 · Source: yfinance · Market: closed_weekend · Cache TTL 360 min
| 1 Day | +1.12% |
| 1 Month | -11.53% |
| 3 Months | -26.76% |
| YTD | -27.99% |
| 1 Year | -14.60% |
| 52-Week High | $354.88 |
| 52-Week Low | $194.61 |
| Market Cap | $14,341,745,664 |
| P/E (Trailing) | 58.54 |
| P/E (Forward) | 25.21 |
| EPS (TTM) | $3.48 |
| Dividend Yield | n/a |
| Beta | 1.47 |
| Revenue (TTM) | $2,708,100,096 |
| Profit Margin | 9.12% |
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.